文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

大剂量维生素C显著降低重症患者万古霉素肾毒性

[High dose vitamin C significantly reduces the nephrotoxicity of vancomycin in critically ill patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论回顾性分析显示,重症患者使用万古霉素时联用大剂量维生素C可改善肾功能并缩短ICU住院时间。

该研究为回顾性分析,纳入2012年1月至2019年10月在上海交通大学医学院附属瑞金医院急诊ICU住院并使用万古霉素或联用维生素C输注的245例患者,分为万古霉素组(127例)和万古霉素联合维生素C组(118例)。联合组qSOFA评分和基线肾功能显著差于万古霉素组,万古霉素日均剂量显著低于万古霉素组。万古霉素使用后肾功能较使用前显著恶化;联用维生素C后SCr较维生素C治疗前显著改善,BUN无显著差异,ICU住院时间显著缩短。作者认为重症患者使用万古霉素时联用维生素C可减少或避免药物性肾损伤。

要点

  • 245例急诊ICU患者中,万古霉素组127例、万古霉素联合维生素C组118例,联合组qSOFA评分和基线肾功能显著更差。
  • 万古霉素使用后肾功能较使用前显著恶化:SCr 68.0(50.2, 104.5)μmol/L vs 56.0(42.2, 71.0)μmol/L,BUN 5.35(3.75, 9.83)mmol/L vs 4.70(3.45, 8.10)mmol/L,均P<0.05。
  • 联用维生素C后SCr较维生素C治疗前显著改善:79.0(58.0, 129.0)μmol/L vs 98.0(65.0, 178.2)μmol/L,P<0.05;BUN 9.60(6.10, 18.30)mmol/L vs 11.30(6.48, 18.38)mmol/L,P>0.05。
  • 联合组ICU住院时间较万古霉素组显著缩短:28.5(14.8, 54.2)天 vs 37.0(25.0, 55.0)天,P<0.01。
  • 维生素C剂量范围为50-200 mg×kg-1×d-1,持续输注,剂量根据患者疾病严重程度确定。

适用人群与场景

  • 2012年1月至2019年10月在上海交通大学医学院附属瑞金医院急诊ICU住院、使用万古霉素或联用维生素C输注的危重症患者。
  • 入ICU原因包括肺部感染、脓毒症、重症急性胰腺炎等;万古霉素组肺部感染占63.0%,联合组重症急性胰腺炎占61.9%。

处置流程与药物剂量

  • 万古霉素初始剂量按患者实际体重计算,并根据肾功能调整。
  • 维生素C剂量根据患者疾病严重程度确定,剂量范围50-200 mg×kg-1×d-1,持续输注。

研究设计与关键结果

  • 回顾性分析纳入245例患者,万古霉素组127例,万古霉素联合维生素C组118例。
  • 联合组qSOFA评分显著高于万古霉素组:1.0(0, 1.0)vs 0(0, 0.2),P<0.01。
  • 联合组基线肾功能显著差于万古霉素组:SCr 98.0(65.0, 178.2)μmol/L vs 56.0(42.2, 71.0)μmol/L,BUN 11.30(6.48, 18.38)mmol/L vs 4.70(3.45, 8.10)mmol/L,均P<0.05。
  • 联合组万古霉素日均剂量显著低于万古霉素组:23.0±9.4 mg×kg-1×d-1 vs 26.6±8.5 mg×kg-1×d-1,P<0.01。
  • 万古霉素使用后肾功能较使用前显著恶化:SCr 68.0(50.2, 104.5)μmol/L vs 56.0(42.2, 71.0)μmol/L,BUN 5.35(3.75, 9.83)mmol/L vs 4.70(3.45, 8.10)mmol/L,均P<0.05。
  • 联用维生素C后SCr较维生素C治疗前显著改善:79.0(58.0, 129.0)μmol/L vs 98.0(65.0, 178.2)μmol/L,P<0.05;BUN 9.60(6.10, 18.30)mmol/L vs 11.30(6.48, 18.38)mmol/L,P>0.05。
  • 联合组ICU住院时间显著短于万古霉素组:28.5(14.8, 54.2)天 vs 37.0(25.0, 55.0)天,P<0.01。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重症患者使用万古霉素时可联用维生素C以减少或避免药物性肾损伤、提高疗效并减少毒性作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the changes of renal function in critically ill patients using vancomycin and analyze the renal protective effect of high dose vitamin C (VC) on vancomycin nephrotoxicity.

METHODS: Retrospective analysis was carried out to enroll the patients who were hospitalized in emergency intensive care unit (ICU) of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2012 to October 2019. All patients were administered with vancomycin or VC infusion in addition. According to the infusion of vancomycin alone or in combination with VC, the patients were divided into vancomycin group and vancomycin in combination with VC group; vancomycin group was further divided into two groups according to before vancomycin or after vancomycin usage; combination group were further divided into two groups according to before VC use or after VC. The initial dosage of vancomycin was calculated according to the actual weight of the patient and adjusted according to the renal function. The dosage of VC was determined according to the disease severity of the patient, and the dosage range was 50-200 mg×kg-1×d-1, continuously infused into the body. The age, gender, weight and renal function etc. were recorded and analyzed.

RESULTS: A total of 245 patients who met the requirements were included in the analysis. There were 127 patients in the vancomycin group and 118 patients in the combination group. The causes of patients admitted to ICU were pulmonary infection, sepsis, severe acute pancreatitis, etc. Among them, pulmonary infection accounted for 63.0% in vancomycin group, while severe acute pancreatitis accounted for 61.9% in combination group. The quick sequential organ failure assessment (qSOFA) score of combination group was significantly higher than that of vancomycin group [1.0 (0, 1.0) vs. 0 (0, 0.2), P < 0.01], its basic renal function was also significantly worse [serum creatinine (SCr, μmol/L): 98.0 (65.0, 178.2) vs. 56.0 (42.2, 71.0), blood urea nitrogen (BUN, mmol/L): 11.30 (6.48, 18.38) vs. 4.70 (3.45, 8.10), both P < 0.05], and the average daily dose of vancomycin was also significantly lower than that of vancomycin group (mg×kg-1×d-1: 23.0±9.4 vs. 26.6±8.5, P < 0.01). Compared with vancomycin before administration, the renal function was getting worse significantly after vancomycin administration [SCr (μmol/L): 68.0 (50.2, 104.5) vs. 56.0 (42.2, 71.0), BUN (mmol/L): 5.35 (3.75, 9.83) vs. 4.70 (3.45, 8.10), both P < 0.05]. Combination with VC significantly improved renal function compared with that before VC treatment [SCr (μmol/L): 79.0 (58.0, 129.0) vs. 98.0 (65.0, 178.2), P < 0.05; BUN (mmol/L): 9.60 (6.10, 18.30) vs. 11.30 (6.48, 18.38), P > 0.05] and shortened the length of ICU stay [days: 28.5 (14.8, 54.2) vs. 37.0 (25.0, 55.0), P < 0.01].

CONCLUSIONS: The incidence of drug-induced renal injury caused by vancomycin is high. Intravenous high dose VC can significantly reduce the nephrotoxicity of vancomycin and shorten the length of hospital stay. When vancomycin is used in critically ill patients, VC can be used in combination to reduce or avoid drug-induced renal injury, improve curative effect and reduce toxic effects.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. He J, Mao E, Xu W, et al. [High dose vitamin C significantly reduces the nephrotoxicity of vancomycin in critically ill patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32527355. doi:10.3760/cma.j.cn121430-20200110-00083

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。